Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366

Featured Application: The potential application of this work lies in the ability to monitor the highest frequencies evoking an otoacoustic emission to assess basal cochlear health in newborns receiving ototoxic treatments.Abstract: Distortion-product otoacoustic emissions (DPOAEs) elicited with high-frequency (HF; up to 16 kHz) stimuli are measurable and repeatable in normal-hearing adults and children, adult patients, and are sensitive to ototoxic insults in adults. However, objective tests for monitoring basal cochlear function in those too young to respond subjectively need to be developed. DPOAE levels recorded at frequencies <10 kHz are well characterized, but DPOAE levels measured up to 16 kHz do not exist for newborns. The goal of the current study is to determine if HF DPOAEs are measurable and repeatable in newborns. DPOAEs were measured from 2-16 kHz (f 2 /f 1 of 1.22; L 1 /L 2 = 65/55 dB SPL) using two different calibration methods (forward pressure level-FPL and in-the-ear-SPL) in 26 newborns. To assess repeatability, the probe was removed then re-inserted for a second round of testing. Results indicate that HF DPOAEs can be evoked and are repeatable in newborns and the use of FPL calibration shows promise for measuring HF responses and maximizing repeatability. To be implemented in monitoring programs where the highest frequencies with responses are continuously tested, stimulus parameters used to evoke newborn HF DPOAEs and calibration methods need further exploration.